Thursday, July 30, 2015 4:26:51 PM
The ideas at this point are not quite mature enough to post as yet - and am doing a bit more research and digging to find comparable numbers in other biotech companies that have made it over that 'hump' to start generating revenues.
Given - even under some of our most optimistic outlooks and thinking - we're at least a year from seeing significant revenue.
But take this as one potential example. Obviously some additional animal testing and some non-ingested TOX testing would need to be done before any clinical testing could start,.... Best guess - at least a year, more likely closer to 2 as we know nothing ever works perfectly out of the box,...
IF a HerpesCide cream/ointment can be manufactured at even at just 500 g batch sizes.
And if each 500 g batch can be aliquoted into individual treatment-size portions with 100 mg of active HerpesCide into whatever carrier base to that ointment is used.
Individual 500 g batches would be divided into 5000 individual portions.
If those 5000 portions were to sell at even $500/treatment that would generate revenue of $2.5 MM. Yes - a sizable portion of that $2.5 M would go to packagers, distributors, and a defined portion would go to TheraCour for their costs & royalties,...
Assume that NNVC was able to retain even 40% if that after all costs and it gives the company $1,000,000 net revenue,....
And if batches can be made at least monthly,.... that's $12 MM net revenue each year,...
With ~60 MM shares (roughly) issued and $12 MM net revenue of $0.20 / share,....
And that's just for one potential 'Cide product. Not even including IV FluCide's potential value.
How many fledgling Pharma companies would love to have a net Earnings per Share of $0.20/year?
What if that is then translated into a P/E value of even a relatively modest 20x? That alone - absent any speculative play on future value is enough to get the ball rolling.
And once Kg-level quantities can be made,... the potential profit goes up even more.
“The two most powerful warriors are patience and time.”
- Leo Nikolaevich Tolstoy
Recent NNVC News
- NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • InvestorsHub NewsWire • 05/02/2024 02:07:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/01/2023 08:46:45 PM
- Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs • InvestorsHub NewsWire • 07/06/2023 03:16:37 PM
FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM